Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany.
Department of Obstetrics and Gynecology, Breast Center, Gynecologic Oncology Center and CCC Munich, LMU University Hospital, Marchioninistraße 15, 81337, Munich, Germany.
Breast. 2021 Dec;60:214-222. doi: 10.1016/j.breast.2021.10.012. Epub 2021 Oct 29.
The side effects of systemic cancer therapy and the lack of clinical data on safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the patients about whether to get vaccinated or not. Here, we evaluated attitude towards and effects of COVID-19 vaccination in patients with breast and gynecological cancer undergoing systemic cancer therapy.
Since March 15th, 2021, cancer patients who received one of the approved COVID-19 vaccines were routinely interviewed about immediate and late side effects. Clinical parameters such as current therapy, time interval between therapy administration and vaccination, and changes in the therapy schedule due to vaccination were documented. The collected data were analyzed de-identified as a part of routine quality assurance.
By July 27th, 2021, 218 patients (74.3% breast cancer patients) had received one of two COVID-19 vaccine doses, and 112 patients had received both doses: 77.5% received Conmirnaty (BioNTech/Pfizer), 16.1% Vaxzevria (Astra Zeneca) and 5.9% COVID-19 Vaccine Moderna. The COVID-19 vaccines had an acceptable safety profile with self-limiting local and systemic adverse events, which rarely lasted >48 h post vaccination. Symptoms occurred predominantly after the second dose of the vaccine and less frequently in older patients >55 years. No vaccine-related serious adverse events were reported, and only limited effects of vaccination on the therapy schedule were observed.
Breast and gynecologic cancer patients tolerate the COVID-19 vaccination while undergoing systemic cancer therapy without any additional side effects beyond those reported in the general population.
全身性癌症治疗的副作用以及 COVID-19 疫苗在癌症患者中的安全性和疗效缺乏临床数据，这使得癌症患者对是否接种疫苗存在不确定性。在此，我们评估了正在接受全身性癌症治疗的乳腺癌和妇科癌症患者对 COVID-19 疫苗接种的态度和效果。
自 2021 年 3 月 15 日起，常规询问接受过一种批准的 COVID-19 疫苗的癌症患者有关即时和迟发性副作用的情况。记录了当前治疗、治疗与接种疫苗之间的时间间隔、以及因接种疫苗而改变治疗方案等临床参数。所收集的数据作为常规质量保证的一部分进行了去识别分析。
截至 2021 年 7 月 27 日，218 名患者（74.3%为乳腺癌患者）已接种了两剂 COVID-19 疫苗中的一剂，112 名患者已接种了两剂：77.5%接种了 Comirnaty（辉瑞/BioNTech），16.1%接种了 Vaxzevria（阿斯利康），5.9%接种了 COVID-19 疫苗 Moderna。COVID-19 疫苗具有可接受的安全性，具有自限性的局部和全身不良事件，这些不良事件在接种后很少持续>48 小时。症状主要发生在疫苗的第二剂后，在年龄较大的>55 岁患者中发生频率较低。未报告与疫苗相关的严重不良事件，仅观察到接种对治疗方案的有限影响。
正在接受全身性癌症治疗的乳腺癌和妇科癌症患者能够耐受 COVID-19 疫苗接种，且除了在普通人群中报告的副作用之外，没有其他额外的副作用。
